Marcy-l’Étoile (France), January 22nd, 2026 – bioMérieux, a world leader in the field of in vitro diagnostics, announces the acquisition of Accellix, a US company specializing in rapid, automated flow cytometry solutions for cell and gene therapy quality control. With this strategic transaction, bioMérieux strengthens its Pharmaceutical Quality Control activity and invests in innovative solutions that will support the growing advanced therapy market and improve patient outcomes worldwide.
Cell and gene therapies are innovative medical treatments that use living cells or genetic modification to repair, replace, or restore function in diseased tissues, offering the potential to cure conditions once considered untreatable. From development to manufacturing, ensuring consistency, safety, and reliability is critical to building trust and unlocking the full promise of these groundbreaking treatments.